⌕
PTC Therapeutics · PTCT · Nasdaq
Tenet 57 · Mixed
Compare
$62.18−2.06%Market openTenet 57 · Mixed
$62.18−1.31 (−2.06%)
Market open · 15-min delayed · as of 12:17 PM ET· Nasdaq · USD

PTC Therapeutics (PTCT) Stock Checks

How PTCT measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.

Sources Company filings and computed by Tenet Filings and TenetScreens as of How we compute thisNot investment advice

The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).

0 / 17 qualify todayas of close, Nov 13, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
0
meet every gate today
BORDERLINE
5
within one input of the gate
FAILS
7
miss at least one gate
UNKNOWN
5
insufficient data to judge
Buffett Qualitydurable moat
— Insufficient inputs (2 of 5 known)
Unknown — no dataROE ≥ 15%— · ≥ 15.0%
PassesGross margin ≥ 40%96.4% · ≥ 40.0%
FailsNet margin ≥ 15%−3.8% · ≥ 15.0%
Unknown — no dataDebt/equity ≤ 0.5— · ≤ 0.50
Unknown — no dataGrowing FCF (multi-yr)— · > 0
Verdict Unknown for this set.
Verdict Unknown for this set. 2 of 5 checks below carry data.Buffett Quality under The screens ›Today's Buffett Quality list ›
PassesReturn on assets positive23.5% · > 0
PassesOperating cash flow positive$711.2M · > 0
PassesReturn on assets improving−21.3% → 23.5%
PassesEarnings backed by cash (CFO > net income)$711.2M vs $682.6M
PassesLeverage falling (long-term debt / assets)16.7% → 0.0%
FailsCurrent ratio improving2.35 → 2.35
FailsNo share dilution (≤ +2%)+14.9%
FailsGross margin expandingThe reported cost of revenue collapses to a level implying a 100% gross margin, which we treat as a data artefact rather than a real margin, so gross margin could not be measured. It still scores 0 under this module's conservative rule (a point is never awarded without evidence), and it is not counted as one of the signals we were able to measure.92.9% → n/a
PassesAsset turnover improving0.47 → 0.60
Decided by the pass rule for Piotroski F-Score.
The pass rule for Piotroski F-Score is what decides that verdict, and it is not restated here. 1 of 9 carry no data.Piotroski F-Score under The screens ›Today's Piotroski F-Score list ›
PassesROIC ≥ 15%29.5% · ≥ 15.0%
PassesNet debt/EBITDA ≤ 3×−10.1× · ≤ 3.0×
FailsAltman Z ≥ 3 (safe zone)0.81 · ≥ 3.00
Decided by the pass rule for Munger Compounders.
The pass rule for Munger Compounders is what decides that verdict, and it is not restated here.Munger Compounders under The screens ›Today's Munger Compounders list ›
PassesEBIT > 0$125.6M · > 0
FailsEarnings yield EBIT/EV ≥ 6%3.4% · ≥ 6.0%
FailsReturn on capital ≥ 25%6.6% · ≥ 25.0%
Decided by the pass rule for Magic Formula.
The pass rule for Magic Formula is what decides that verdict, and it is not published separately on the methodology page.About this screen ›Today's Magic Formula® list ›
PassesSize: market cap ≥ $2B$5.3B · ≥ $2.0B
PassesCurrent ratio ≥ 23.39 · ≥ 2.00
FailsPositive EPS 10y1y
FailsPays a dividend$0.00 · > 0
Unknown — no dataEPS growth ≥ 3%/yr— · ≥ 3.0%
Unknown — no dataP/E ≤ 15— · ≤ 15.00
Unknown — no dataP/E × P/B ≤ 22.5— · ≤ 22.50
Decided by the pass rule for Graham Defensive.
The pass rule for Graham Defensive is what decides that verdict, and it is not restated here. 3 of 7 carry no data.Graham Defensive under The screens ›Today's Graham Defensive list ›
Unknown — no dataPEG < 1 (hist. growth)— · < 1.00
Unknown — no dataEPS growth 10–30%— · 10.0%–30.0%
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 2 checks below carry data.Lynch GARP under The screens ›Today's Lynch GARP list ›
FailsPays a dividend$0.00 · > 0
Unknown — no dataYield in a healthy band (not a yield trap)0.0% · 1.0%–8.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataEarnings payout not stretched— · ≤ 75.0%
Unknown — no dataBalance sheet can sustain the payout−10.1× · ≤ 4.0×
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 5 checks below carry data. The pass rule for Income & Dividend Safety is not published separately on the methodology page.
FailsPays a dividend$0.00 · > 0
Unknown — no dataAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)— · ≥ 10.00
Unknown — no dataNo dividend cut in the last 5 years—
Unknown — no data5-year dividend growth ≥ 5%/yr— · ≥ 5.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataPayout not stretched— · ≤ 75.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 6 checks below carry data.Dividend Growth under The screens ›Today's Dividend Growth list ›
FailsReturn on invested capital ≥ 15% in 4+ of the last 5 years0 of 2 on file
PassesRevenue compounding ≥ 8%/yr over 5 years35.4% · ≥ 8.0%
FailsNot diluting: diluted share count flat-to-down (≤ +1%/yr)7.0% · ≤ 1.0%
FailsFree cash flow margin ≥ 12%−3.9% · ≥ 12.0%
Not scored: see the reason belowEarnings backed by cash (operating cash flow ≥ net income)A loss year makes cash-vs-earnings unreadable: the ratio inverts over negative net income, so it is not scored (never counted against).— · ≥ 1.00
Reading: does not hold. Not a gate checkDisciplined buybacks: actively reducing the share count (bonus)reading, not a gate check7.0%
Decided by the pass rule for Quality Compounder.
The pass rule for Quality Compounder is what decides that verdict, and it is not restated here. 1 of 5 carry no data. Lines marked as readings are published beside the checks and are not gate checks.Quality Compounder under The screens ›Today's Quality Compounder list ›
PassesOff its 52-week high by 8–35% (a dip, not a collapse)30.1% · 8.0%–35.0%
PassesDip within its own normal pullback band0.09
PassesNot past where its dips have historically recovered from0.56
FailsA dip in an uptrend (above a rising 200-day)70.16
FailsHigher-low structure still intactstructure intact · no higher low
Unknown — no dataClear of the earnings blackout (more than 5 days out)— · > 5.00
Decided by the pass rule for Drawdown Context.
The pass rule for Drawdown Context is what decides that verdict, and it is not published separately on the methodology page. 1 of 6 carry no data.
FailsA bullish MACD cross within 10 sessions18.00 · ≤ 10.00
FailsReclaimed a rising 50-day EMA65.10
FailsPrinted a higher lowno
FailsA volume thrust on the turn (≥ 1.2× normal)1.05 · ≥ 1.20
FailsReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)0.00 · ≥ 3.00
Decided by the pass rule for Reversal Evidence.
The pass rule for Reversal Evidence is what decides that verdict, and it is not published separately on the methodology page.
Unknown — no dataIn the cheap half of its own 5-year valuation range—
FailsEarnings estimates not being cut−0.60
Unknown — no dataReturns on capital not deteriorating−1.99
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 3 checks below carry data. The pass rule for Not-a-Value-Trap Gate is not published separately on the methodology page.
PassesOperating profit is positive$125.6M · > 0
PassesReturn on invested capital ≥ 10%29.5% · ≥ 10.0%
FailsA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)0.8×
PassesQuality score ≥ 5060.80 · ≥ 50.00
PassesRevenue growing over 5 years35.4% · > 0
Decided by the pass rule for Quality Floor.
The pass rule for Quality Floor is what decides that verdict, and it is not published separately on the methodology page.
A research signal from published criteria, not a recommendation.
FailsDrawdown context30.1% off its 52-week high
FailsReversal evidence0 of 4 signals fired
Unknown — no dataTrap gate0 of 3 held · 2 no data
FailsQuality floor4 of 5 held
Invalidation level (structure break): below this the dip's structure has broken$59.24
Decided by the pass rule for Qualified Dip.
The pass rule for Qualified Dip is what decides that verdict, and it is not restated here. 1 of 4 carry no data.Qualified Dip under The screens ›Today's Qualified Dip list ›
FailsTrading above its 50-day average64.12
FailsTrading above its 200-day average70.16
Fails50-day average above the 200-day (uptrend stack)64.12
Fails50-day average sloping up−0.05 · > 0
Decided by the pass rule for Trend Alignment.
The pass rule for Trend Alignment is what decides that verdict, and it is not published separately on the methodology page.
Fails3-month return in the top half of the universe0.28 · ≥ 0.50
Fails12-minus-1 momentum in the top half of the universe0.17 · ≥ 0.50
FailsRelative strength vs the S&P 500 improving−0.00 · > 0
FailsEarnings estimates being revised up−0.60
Decided by the pass rule for Relative Strength.
The pass rule for Relative Strength is what decides that verdict, and it is not published separately on the methodology page.
PassesMACD above its signal line0.17
FailsBack above the 50-day on a fresh cross (≤10 sessions)18.00
FailsHigher high and higher low (stair-stepping up)no higher high · no higher low
FailsA volume thrust on the move (≥ 1.2× normal)1.05 · ≥ 1.20
Decided by the pass rule for Momentum Trigger.
The pass rule for Momentum Trigger is what decides that verdict, and it is not published separately on the methodology page.
Average daily swing: elevated0.04
Volatility band width: mid-range0.50
Distance from its 52-week high: a deep pullback0.30
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.

How many investing rule sets does PTC Therapeutics pass?

PTC Therapeutics qualifies on 0 of 17 rule sets as of 2026-11-13, with 5 borderline and 7 failing.

Does PTC Therapeutics meet the Graham Defensive criteria?

PTC Therapeutics fails the Graham Defensive rule set as of 2026-11-13.

Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.